Stock AnalizTaysha Gene Therapies, Inc. TSHA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Taysha Gene Therapies, Inc. (TSHA) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$156M, a net margin of -2844.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -88%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $10M | $8M | $15M | $3M | — | — |
| Net income | -$156M | -$109M | -$89M | -$112M | -$166M | -$175M | -$60M |
| Free cash flow | -$142M | -$94M | -$82M | -$77M | -$109M | -$132M | -$31M |
| EPS (diluted) | $-0.43 | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 |
| Net margin | -2844.6% | -1115.3% | -1071.6% | -722.1% | -6635.3% | — | — |
| ROIC | — | -27.6% | -53.8% | -42.2% | -211.9% | -103.2% | -13.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $13.00, 217% above the current price; targets range from $9.00 to $19.00; the consensus rating is “Strong buy”; expected EPS is $-0.43 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Taysha Gene Therapies pay a dividend?
Not currently.
Is Taysha Gene Therapies a good stock to buy?
We do not give buy or sell advice. Taysha Gene Therapies scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.